Thermo Fisher Scientific EDA2R Monoclonal Antibody (5D7E3)

Applications

Tested Dilution

Publications

ELISA (ELISA)

1:1,000-1:2,000

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

5D7E3

Immunogen

Recombinant Human XEDAR/EDA2R protein (Met1-Thr138) if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:EDA2R,uniProtId:Q9HAV5-1,ncbiNodeId:9606,antigenRange:1-138,antigenLength:297,antigenImageFileName:MA5-30353_EDA2R_Q9HAV5-1_House_mouse.svg,antigenImageFileNamePDP:MA5-30353_EDA2R_Q9HAV5-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Protein A

Storage buffer

PBS

Contains

no preservative

Storage conditions

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2786097

Product Specific Information

This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%).

This antibody has specificity for Human XEDAR/EDA2R.

Target Information

X-linked ectodysplasin-A2 receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that is highly expressed during embryonic development and binds to ectodysplatin-A2 (EDA-A2). Two predominantly expressed isoforms, XEDAR-s and XEDAR-L, differ by only a 21-amino region at the juxtamembrane region of the cytoplasmic domain. Neither isoform possesses a death domain and both have been shown to act mainly through TRAF3 and TRAF6 to activate the NF-kappa-B and JNK pathways. Cells transfected with XEDAR and treated with EDA-A2 cause the assembly of a secondary complex containing FADD, caspase-8 and caspase-10, leading to the activation caspase-8 and caspase-3, and finally apoptosis. The EDA-A2-induced apoptosis is dependent on caspase-9 activation, as various pharmacological and genetic inhibitors of caspase-8 blocked apoptosis following EDA-A2 treatment.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.